If you are unfamiliar with the name Clay Siegall then you’re probably not alone, this individual has done major things in cancer research throughout the years and is well respected among his peers. He’s the author of 70 publications, has a Ph.D in Genetics, (BS) in Zoology, and known to many as a scientist. Dr. Clay Siegall is CEO and President of Biotech Company Seattle Genetics. Seattle Genetics of Bothell, Washington specializes in the development and commercialization of antibody based therapies and is one of the top companies in the world for doing this. Dr. Siegall has built a sturdy foundation for the company ever since it’s inception in the late 90’s. Dr. Siegall’s role span into capital raising as well as he has secured over $1.2 Billion through private and public financing.
The company’s flagship drug ADCETRIS is currently being used in over 65 countries worldwide thanks to Dr. Siegall’s savvy business sense. The business sense has allowed him to enter the company’s (ADC) Antibody Drug Conjugates into multiple licensed agreements with some really huge industry names which has resulted growth earning of up to $225 Million in 2015 for Canada and the U.S. Future projections are looking to be around $255-$275 Million for 2016. Forbes Magazine has ranked Seattle Genetics as one of the fastest growing companies in the nation as well for last year. There are numerous drugs already in the pipeline and advancement stages which will result in another hiring blitz well into the future.
The success of these innovative antibody drug conjugates is that they deliver cell killing agents straight into cancerous cells while sparing non-targeted cells. The treatments are far more advanced than treatments of the past which resulted in nasty side effects. Dr. Clay Siegall’s winning strategy is now the blueprint of success in this ever changing field of work and Seattle Genetics is standing at the apex of the industry for doing so.